Skip to content
HCN Grants Est. 2026
No. HT942526PRPIIRA · Defense Health Agency Contracting Activity - DHACA
Open

DoW Parkinson’s, Investigator-Initiated Research Award

Dealbreakers No cost share required Audit: not stated Reimbursement-only: not stated

At a glance

This program funds rigorous Parkinson’s disease research that addresses at least one of the program’s FY26 focus areas, including disease biology, model systems, biomarkers, and interventions. Eligible applicants include U.S. Department of War organizations and foreign or domestic, for-profit or nonprofit organizations, and awards are made to organizations, not individuals. The program expects to fund about five awards with roughly $10 million total, with a maximum of $2 million in total costs per award and a maximum project period of 3 years. Cost sharing is not required, and the announcement allows clinical trials and multidisciplinary collaborations; it does not state any geographic restriction beyond eligibility for U.S. Department of War, U.S., foreign, and domestic organizations.

AI-generated summary — verify against the announcement

What it funds

  • Science and Technology and other Research and Development
  • Research & Discovery
  • Patients & People with Health Conditions
  • Biomedical & Disease Research
Official description from grants.gov

Summary: The fiscal year 2026 (FY26) Parkinson’s Research Program (PRP) Investigator-Initiated Research Award (IIRA) supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to Parkinson’s disease research. Research must address at least one of the four FY26 PRP Focus Areas . Distinctive Features: · Partnering Principal Investigator (PI) Option: Allows for more than one PI. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI(s) will be identified as Partnering PI(s), with a maximum of two Partnering PIs. · Preliminary data are required. · Clinical trials are allowed.

Who can apply

  • Unrestricted
Geographic restriction None found in the announcement — likely nationwide